Compounds targeting pax3::foxo1 fusion protein
AssigneeGeorgetown University
InventorsAykut Üren, Jeffrey A. Toretsky
Life of this patent
Estimating the term…
Abstract
Compounds comprising a PAX3::FOXO1 fusion protein binding moiety, a bivalent linker, and an E3 ubiquitin ligase binding moiety. The compounds can be used to reduce PAX3::FOXO1 protein levels in a subject with fusion-positive rhabdomyosarcoma (FP-RMS), to ubiquitinate a PAX3::FOXO1 fusion protein in a cell, to treat FP-RMS in a subject in need thereof, and/or to treat a disease caused by the overexpression of PAX3::FOXO1 protein in a subject in need thereof.
Claims30
A compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
- P is a PAX3::FOXO1 fusion protein binding moiety;
- L is a bivalent linker;
- and
- U is an E3 ubiquitin ligase binding moiety;
- and
- wherein the PAX3::FOXO1 fusion protein binding moiety comprises an agent selected from Table 1 or a derivative thereof.
(canceled)
(canceled)
9-13. (canceled)
15-16. (canceled)
18-19. (canceled)
(canceled)
(canceled)
32-33. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.